Creative Planning
CRVS icon

Creative Planning’s Corvus Pharmaceuticals CRVS Stock Holding History

Creative Planning’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$630K Buy
43,032
+3,854
+10% +$61.5K ﹤0.01% 2842
2025
Q4 		$302K Buy
39,178
+13,879
+55% +$109K ﹤0.01% 3232
2025
Q3 		$186K Buy
+25,299
New +$129K ﹤0.01% 3517

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Creative Planning's CRVS Position: Q1 2026 in Review

Creative Planning increased its Corvus Pharmaceuticals (CRVS) stake by 9.8% in Q1 2026, buying an estimated $61.5K and bringing the position to 43,032 shares worth $630K. The position accounts for ﹤0.01% of the portfolio, ranked #2842.

Creative Planning first reported a position in CRVS in Q3 2025 and has held it in 3 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Creative Planning held 43,032 shares of Corvus Pharmaceuticals worth $630K as of Q1 2026.
  • Creative Planning bought 3,854 Corvus Pharmaceuticals shares in Q1 2026, an estimated $61.5K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #2842 holding.
  • Creative Planning first reported a position in Corvus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.